ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "autoimmune diseases"

  • Abstract Number: L19 • 2019 ACR/ARP Annual Meeting

    Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients

    Simon Bowman1, Robert Fox 2, Thomas Dörner 3, Xavier Mariette 4, Athena Papas 5, Thomas Grader-Beck 6, Benjamin A. Fisher 7, Filipe Barcelos 8, Salvatore De Vita 9, Hendrik Schulze-Koops 10, Robert J. Moots 11, Guido Junge 12, Janice Woznicki 13, Monika Sopala 12, Wen-Lin Luo 13 and Wolfgang Hueber 12, 1University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, 2Scripps Memorial Hospital and Research Institute, La Jolla, California, 3Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, 4Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, 5Tufts School of Dental Medicine, Massachusetts, 6Johns Hopkins University, Baltimore, 7University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, 8Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, 9Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, 10Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, 11Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, 12Novartis Pharma AG, basel, Switzerland, 13Novartis Pharmaceuticals Corporation, New Jersey

    Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
  • Abstract Number: 1077 • 2019 ACR/ARP Annual Meeting

    Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications

    Christina Chambers1, Gretchen Bandoli 2, Namrata Singh 3, Jennifer Strouse 4, Rebecca Baer 5, Brittney Donovan 6, Sky Feuer 7, Nichole Nidey 6, Kelli Ryckman 6 and Laura Jelliffe-Pawlowski 7, 1University of California San Diego, La Jolla, 2University of California, San Diego, La Jolla, 3University of Iowa, Iowa City, 4University of Iowa Hospitals and Clinics, Iowa City, 5UCSD, La Jolla, 6UIOWA, Iowa City, 7UCSF, San Francisco

    Background/Purpose: Autoimmune conditions are associated with an increased risk of adverse pregnancy complications and outcomes, suggesting that pregnancy complications may mediate the excess risk. We…
  • Abstract Number: 2296 • 2019 ACR/ARP Annual Meeting

    Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease

    Elisa Trujillo1 and Erika Padrón 1, 1Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: Women with chronic inflammatory and autoimmune diseases increasingly solicit assisted reproductive techniques (ART) due to infertility, but there is little information about success rates…
  • Abstract Number: 1270 • 2019 ACR/ARP Annual Meeting

    Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study

    Martin Michaud1, Thomas Sene 2, Pascal Chazerain 2, Geoffrey Urbanski 3, Frederique Retornaz 4, Boris Bienvenu 5, Laurent Chiche 4, Florian Catros 6, Laurent Sailler 7, Laurent Alric 8, Jean Thomas Giraud 9, Léo Caudrelier 10, Slim Lassoued 10, Sophie Ancellin 6, Olivier Lidove 2 and Francis Gaches 6, 1Joseph Ducuing Hospital, Toulouse, France, 2Hôpital Croix Saint Simon, Paris, France, 3CHU Angers, Angers, France, 4Hôpital Européen, Marseille, France, 5Hôpital Saint Joseph, Marseille, France, 6Hôpital Joseph Ducuing, Toulouse, France, 7University Hospital of Toulouse, Toulouse, France, 8CHU Toulouse, Toulouse, France, 9Hôpital de Tarbes, Tarbes, France, 10Hôpital de Cahors, Cahors, France

    Background/Purpose: There is increasing evidence of Tocilizumab (TCZ) efficacy in refractory auto-immune diseases. The present study aimed at evaluating the real-world experience of using TCZ…
  • Abstract Number: 2736 • 2019 ACR/ARP Annual Meeting

    Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus

    Goh Murayama1, Asako Chiba 2, Tomohiro Mizuno 3, Atsushi Nomura 2, Taiga Kuga 4, HIrofumi Amano 4, Ken Yamaji 4, Naoto Tamura 4 and Sachiko Miyake 2, 1Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, 3Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate T cells that are restricted by the nonpolymorphic MHC-related molecule-1 (MR1) and express a semi-invariant TCRα chain:…
  • Abstract Number: 1295 • 2019 ACR/ARP Annual Meeting

    Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells

    Lauren Pachman1, Wil Marin 2, Gabrielle Morgan 1, Megan L. Curran 3, Kaveh Ardalan 4, Chiang-Ching Huang 5 and Eli Roberson 6, 1Northwestern University, Chicago, 2Ann and Robert H. Lurie Childrens Hospital of Chicago, Chicago, IL, 3University of Colorado, Aurora, CO, 4Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 5University of Milwaukee, Milwaukee, WI, 6Washington University at St.Louis, St.Louis, MO

    Background/Purpose: Juvenile Dermatomyositis (JDM) is a rare inflammatory myopathy in which the immunoregulatory control is not well understood.  Collaboration with A.R.  French, MD/PhD, documented   the…
  • Abstract Number: 2741 • 2019 ACR/ARP Annual Meeting

    Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States

    Fan Zhang1, Joseph Mears 1, ilya Korsunsky 1, Kevin Wei 2, Anna Helena Jonsson 2, Deepak Rao 1, Edy Kim 3, Laura Donlin 4, Jill Buyon 5, Michelle Petri 6, Chaim Putterman 7, Thomas Tuschl 8, Nir Hacohen 9, Betty Diamond 10, Michael Brenner 11 and Soumya Raychaudhuri 1, 1Brigham and Women's Hospital, Boston, MA, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Brigham and Women's Hospital, Boton, MA, 4Hospital For Special Surgery, New York, NY, 5New York University School of Medicine, New York, NY, 6Johns Hopkins University School of Medicine, Baltimore, MD, 7Albert Einstein College of Medicine, New York, NY, 8Rockefeller Research Laboratories, New York, 9Broad Institute, Cambridge, 10Feinstein Institutes for Medical Research, Manhasset, 11Brigham and Women’s Hospital:, Boston

    Background/Purpose: Different autoimmune diseases can co-exist in an individual and share similar genetic associations, autoimmune signaling pathways, and clinical manifestations. However, autoimmune diseases present varied…
  • Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting

    Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis

    Elizaveta Efuni 1, Samuel Cytryn 2, Patrick Boland 2 and Sabina Sandigursky3, 1New York University School of Medicine, New York, NY, 2NYU Langone Health, New York, 3NYU Langone Health, New York, NY

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
  • Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting

    Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation

    Celline C. Almeida-Brasil 1, Evelyne Vinet 2, Christian Pineau 2 and Sasha Bernatsky1, 1Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 2McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…
  • Abstract Number: 1628 • 2019 ACR/ARP Annual Meeting

    Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom

    Aryeh Fischer1, Oliver Distler 2, Dinesh Khanna 3, Yannick Allanore 4, Anna Maria Hoffmann-Vold 5, Gabriele Valentini 6, Toby Maher 7, Martin Aringer 8, Leslie Meng 9, Margarida Alves 10, Martina Gahlemann 11, Manuel Quaresma 10 and Masataka Kuwana 12, 1University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, 4Dept. of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France, 5Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 6Dipartimento di Medicina di Precisione, II Policlinico U.O. Reumatologia, Napoli, Italy, Napoli, Italy, 7National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom, 8Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, 9Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 11Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 12Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan

    Background/Purpose: Interstitial lung disease (ILD) is a common and usually early manifestation of systemic sclerosis (SSc). Decline in lung function in patients with SSc-ILD is…
  • Abstract Number: 2841 • 2019 ACR/ARP Annual Meeting

    A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis

    Yoo Jung Kim1, Elena Schiopu 2, Katalin Dankó 3, Tahseen Mozaffar 4, Srinivas Chunduru 5, Kirstin Lees 6, Namita Goyal 4, David Fiorentino 7 and Kavita Sarin 7, 1Stanford University School of Medicine, Redwood City, CA, 2Department of Rheumatology, University of Michigan, Ann Arbor, 3Department of Clinical Immunology, Medical Faculty, University of Debrecen, Debrecen, Hungary, 4Department of Neurology, University of California Irvine, Irvine, CA, 5Idera Pharmaceuticals, Inc., Cambridge, MA, 6Idera Pharmaceuticals, Inc., Cambridge, 7Department of Dermatology, Stanford University School of Medicine, Redwood City, CA

    Background/Purpose: Dermatomyositis (DM) is a rare inflammatory disease of skin and muscle associated with characteristic skin findings, muscle weakness, interstitial lung disease, pruritus, and malignancies.…
  • Abstract Number: 62 • 2019 ACR/ARP Annual Meeting

    Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway

    Song Guo Zheng1, Julie Wang 2, Junlong dang 3, Nancy Olsen 4 and Wael Jarjour 1, 1Ohio State College of Medicine, Columbus, OH, 2Ohio State University, columbus, 3Sun Yat-sen University, Guangzhou, 4Penn State University, Hershey, PA

    Background/Purpose: Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE) in spite of numerous targets examined and clinical trials conducted.  Mesenchymal…
  • Abstract Number: 1636 • 2019 ACR/ARP Annual Meeting

    Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial

    Maureen Mayes1, Kristin Highland 2, Martina Gahlemann 3, Aryeh Fischer 4, Ganesh Raghu 5, Mannaig Girard 6, Margarida Alves 7, Susanne Stowasser 7, Jörg Distler 8, Marco Matucci-Cerinic 9, Elizabeth Volkmann 10, Masataka Kuwana 11 and Oliver Distler 12, 1Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 2Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, 3Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland, Basel, Switzerland, 4University of Colorado School of Medicine, Denver, Colorado, USA, Denver, CO, 5University of Washington, Seattle, USA, Seattle, 6Boehringer Ingelheim France S.A.S., Reims, France, Reims, France, 7Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 8Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, 9University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, 10University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, 11Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, 12Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland

    Background/Purpose: The presence of anti-topoisomerase I antibody (ATA) in patients with systemic sclerosis (SSc) has been associated with a greater risk of developing interstitial lung…
  • Abstract Number: 102 • 2019 ACR/ARP Annual Meeting

    Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)

    Takayuki Katsuyama1, Kotaro Otomo 1, Hao Li 2, Michihito Kono 3, Nobuya Yoshida 1, George Tsokos 1 and Vaishali R. Moulton 1, 1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 2Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 3Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan

    Background/Purpose: CD4 T helper 1 (Th1) and Th17 cells producing IFN-γ and IL-17 are aberrantly increased and contribute to inflammatory responses in autoimmune diseases including…
  • Abstract Number: 1643 • 2019 ACR/ARP Annual Meeting

    Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use

    Madelon Vonk1, Oliver Distler 2, Daniel Furst 3, Eric Hachulla 4, Sindhu Johnson 5, Shervin Assassi 6, Leslie Meng 7, Manuel Quaresma 8, Margarida Alves 8, Emmanuelle Clerisme-Beaty 8 and Wim Wuyts 9, 1Department of Rheumatology, Radboud University Medical Center, Nijmegen, The Netherlands, Nijmegen, Gelderland, Netherlands, 2Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, 3University of California, Los Angeles, CA, 4Dept. of Internal Medicine and Clinical Immunology, Hôpital Claude Huriez, University of Lille, Lille, France, Lille, France, 5Toronto Scleroderma Program, Department of Medicine, Toronto Western and Mount Sinai Hospitals, University of Toronto, Toronto, Canada, Toronto, Canada, 6Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, Texas, USA, Houston, TX, 7Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Ridgefield, 8Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, 9Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium, Leuven, Belgium

    Background/Purpose: In the SENSCIS trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib reduced the rate of decline in forced vital capacity (FVC)…
  • 1
  • 2
  • 3
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.